Letter From Patanè Regarding Article, "Atrial Fibrosis and Conduction Slowing in the Left Atrial Appendage of Patients Undergoing Thoracoscopic Surgical Pulmonary Vein Isolation for Atrial Fibrillation"
To the Editor:
I have read the article by Krul et al 1 with great interest and congratulate the authors on their excellent work. However, I would like to point out 2 points that need further clarification. First, the authors have reported that the amount of fibrosis was unrelated to conduction velocity or patient characteristics. Previous researches report that older patients experience an increase in the longitudinal conduction velocity and a decrease in transverse velocity compared with younger patients and that aging is the most consistent predictor of developing atrial fibrillation (AF) because of remodeling and fibrosis. 2 How do the authors explain these apparently conflicting observations?
Second, the authors have reported that no myofibroblasts were detected in the left atrial appendage. In previous researches, myofibroblasts have been found in left atrial appendage in patients with and without AF, colocalized with Periodic Acid-Schiff stain-positive glycogen storage cells. 3 Moreover, in patients with AF, activation of angiotensin II, transforming growth factor-β, endothelin-1 (ET-1), and connective tissue growth factor has led to the activation and proliferation of cardiac fibroblasts, leading to myofibroblasts and collagen synthesis, and angiotensin II and transforming growth factor-β are also involved in extracellular matrix degradation. 4 Both an adrenergic enhanced connexin 43 expression and a negative connexin 43 regulation as a result of adrenergic MiR-1 induction have been found in different remodeling stages, and the involvement of the β-adrenergic and muscarinic system in fibroblast activation and transformation and in collagen breakdown regulation is still not fully elucidated. 4 Furthermore, anti-M2-R antibodies could play an important role in the induction and perpetuation of AF, correlating with fibrosis severity, adverse remodeling, and AF recurrence after ablation. 5 I would also like to point out that the authors have reported no relationships with Periodic Acid-Schiff stain-positive glycogen storage cells, angiotensin II, transforming growth factor-β, ET-1, connective tissue growth factor, Mir-s levels, adrenergic and muscarinic system, and anti-M2-R antibodies.
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